Skip to main content

Emerging Treatments in Geographic Atrophy: Reason for Hope?

Release Date: July 27, 2023
Expiration Date: July 27, 2024

Note: If you have already attended the 2023 Summit Series Live Event, you will not be able to log enduring credits

Activity Overview

This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will review the quality-of-life impact of geographic atrophy (GA) and examine current and emerging treatment approaches, including complement inhibitors and other pathways, such as neuroprotective agents and gene therapy. Discussion will include the rationale for various treatment approaches in GA and examine the safety and efficacy data from key clinical trials.

Target Audience

This activity is designed for an audience of ophthalmologists, optometrists, and other members of the healthcare team who treat patients with GA.

Learning Objectives

Upon completion of the educational activity, participants should be able to:
  • Recognize the burden of GA secondary to age-related macular degeneration and its negative impact on quality of life
  • Evaluate the latest efficacy and safety data from clinical trials of complement system inhibitors
  • Review current and emerging approaches for monitoring and treating GA

Criteria for Success

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and International Healthcare Media, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE - Optometrists

AKH Inc., Advancing Knowledge in Healthcare designates this asynchronous activity for a maximum of 1.0 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

This activity is supported by independent educational grants from Alcon, Genentech, Regenxbio, Tarsus, Théa, and Visus.
Name Relationship Commercial Interest
Nadia Waheed, MD, MPH (faculty)

 Consultant Zeiss
 Consultant Topcon (imaging research)
 Consultant Ocudyne
 Consultant Stealth
 Consultant Novartis
 Consultant Complement Therapeutics
 Consultant Johnson & Johnson Vision
 Consultant Saliogen
 Consultant Valitor
 Consultant Olix
Employee AGTC
Andrew Moshfeghi, MD, MBA (faculty)

Consultant, Research Regeneron
Consultant, Research
Consultant, Research
Consultant Alimera
Consultant, Stock Ocular Therapeutix
Consultant, Stock Valitor

Consultant Ainsly ltd; dba Waldo
Consultant Pr3vent
Session Planners/Reviewers/Accreditors

Dorothy Caputo, MA, BSN, RN - VP, Healthcare
Continuing Education and Operations
N/A Nothing to disclose
Michele Bielarski, RN (planner/reviewer) N/A Nothing to disclose
AKH Inc. Staff and Planners N/A Nothing to disclose
International Healthcare Media dba
International Healthcare Education Staff and
N/A Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.